References
- Lumish M, Falchi L, Imber BS, Scordo M, Von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J Hematol Oncol 2021;14:5.
- Zenhauser R. Indolent lymphomas: classification, clinic and treatment. Practice 2013;102:399-406.
- Flinn IW, Van Der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood 2014;123:2944-52.
- Flinn IW, Van Der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin Oncol 2019;37:984-91.
- Rummel MJ, Niederle N, Maschmeyer G, Banat GA, Von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10.
- Dewilde S, Woods B, Castaigne JG, Parker C, Dunlop W. Bendamustine-rituximab: A cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales. J Med Econ 2014;17:111-24.
- Sapkota S, Shaikh H. Non-hodgkin lymphoma. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559328 [Last accessed on 2023 Nov 15].
- Kazmi T, Nagi M, Razzaq S, Hussnain S, Shahid N, Athar U. Burden of noncommunicable diseases in Pakistan. East Mediterr Health J 2022;28:798-804.
- Ahmad M, Khan AH, Mansoor A, Khan MA, Saeed S. Non-Hodgkin’s lymphoma--clinicopathological pattern. J Pak Med Assoc 1992;42:205-7.
- Saleem R, Chughtai A, Zafar G, Chughtai O, Javeed S, Chughtai AS. Clinicopathological spectrum of B-cell Non-Hodgkin lymphoma in Pakistan population: A single-center study. Cureus 2023;15:e34298.
- Aftab K, Bhurgri Y, Pervez S. Small B cell Non-Hodgkins lymphoma in Pakistan. J Pak Med Assoc 2006;56:22-5.
- Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 2022;97:1638-51.
- Scarfò L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol 2016;104:169-82.
- Bond DA, Huang Y, Ruppert AS, Walker AR, Dotson EK, Roddy J, et al. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell Non-Hodgkin lymphoma based on initial starting dose. Leuk Lymphoma 2017;58:1589-97.
- Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, et al. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: Multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. Eur J Cancer 2016;60:154-65.
- Castelli R, Gidaro A, Deliliers GL, Bergamaschini L. Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments. Anticancer Drugs 2021;32:323-9.
- Morigi A, Argnani L, Lolli G, Broccoli A, Pellegrini C, Nanni L, et al. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: Experience on 65 patients. Hematol Oncol 2020;38:487-92.
- Paikaray SK, Gogia A, Kumar L, Sharma A, Biswas AA, Vishnubhatla S, et al. A phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma. Indian J Cancer 2023;60:501-4.
- Gogia A, Kumar S, Kumar L, Sharma A, Mallick S. Safety and efficacy of bendamustine-rituximab in treatment naïve symptomatic follicular lymphoma: An institutional analysis. Indian J Hematology Blood Transfusion 2021;37:169-70.